Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

Douglas G Altman, Lisa M McShane, Willi Sauerbrei, Sheila E Taube, Douglas G Altman, Lisa M McShane, Willi Sauerbrei, Sheila E Taube

Abstract

Background: The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist consists of 20 items to report for published tumor marker prognostic studies. It was developed to address widespread deficiencies in the reporting of such studies. In this paper we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report.

Methods: REMARK recommends including a transparent and full description of research goals and hypotheses, subject selection, specimen and assay considerations, marker measurement methods, statistical design and analysis, and study results. Each checklist item is explained and accompanied by published examples of good reporting, and relevant empirical evidence of the quality of reporting. We give prominence to discussion of the 'REMARK profile', a suggested tabular format for summarizing key study details.

Summary: The paper provides a comprehensive overview to educate on good reporting and provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general. To encourage dissemination of the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration, this article has also been published in PLoS Medicine.

Figures

Figure 1
Figure 1
Example of a participant flow diagram. [177]
Figure 2
Figure 2
Frequency distribution of Steroid Receptor RNA Activator Protein (SRAP) H-scores in 372 breast tumors, showing median of 76.67 used to delineate low and high subgroups [179] (for a secondary example see Figure 1 in [29]).
Figure 3
Figure 3
Kaplan-Meier plot for disease-free survival comparing patients with HU177 concentrations above and below the median value. [178].

References

    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer. 2005;93:387–391.
    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst. 2005;97:1180–1184.
    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK) Eur J Cancer. 2005;41:1690–1696.
    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–9072.
    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat Clin Pract Oncol. 2005;2:416–422.
    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat. 2006;100:229–235.
    1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (remark) Exp Oncol. 2006;28:99–105.
    1. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–1991.
    1. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
    1. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979–985.
    1. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat. 1998;52:289–303.
    1. Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology. 1999;35:489–494.
    1. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003;88:1191–1198.
    1. Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Adv Otorhinolaryngol. 2005;62:184–200.
    1. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97:1043–1055.
    1. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007;99:236–243.
    1. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009;100:1219–1229.
    1. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer. 2010;102:173–180.
    1. Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP. New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. Pancreas. 2011;40:522–532.
    1. Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA. 2001;285:1996–1999.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
    1. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S, Landberg G. Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst. 2009;101:1725–1729.
    1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
    1. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000;92:1805–1811.
    1. Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009;24:1–10.
    1. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529–536.
    1. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer. 1999;79:300–307.
    1. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008;26:4595–4602.
    1. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009;15:5258–5266.
    1. Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005;23:8313–8321.
    1. Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer. 2004;91:4–8.
    1. de Mascarel I, Bonichon F, Durand M, Mauriac L, MacGrogan G, Soubeyran I, Picot V, Avril A, Coindre JM, Trojani M. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998;34:58–65.
    1. Cho H, Kang ES, Kim YT, Kim JH. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest. 2009;27:313–323.
    1. Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Muller-Hermelink HK, Ott G, Rosenwald A, Campo E. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol. 2008;26:4966–4972.
    1. Djidja MC, Claude E, Snel MF, Scriven P, Francese S, Carolan V, Clench MR. MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. J Proteome Res. 2009;8:4876–4884.
    1. Best practices for biospecimen resources.
    1. Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol. 2008;26:5638–5644.
    1. International Society for Biological and Environmental Repositories (ISBER) 2008 Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Cell Preserv Technol. 2008;6:5–58.
    1. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hainaut P, Hayes DF, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen reporting for improved study quality (BRISQ) Biopreservation Biobanking. 2011;9:57–70.
    1. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173–182.
    1. Hammond ME, Barker P, Taube S, Gutman S. Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol. 2003;11:103–106.
    1. van den Broek LJCM, van de Vijver MJ. Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol. 2000;8:316–321.
    1. Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004;13:667–672.
    1. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005;5:142–149.
    1. Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009;15:2116–2122.
    1. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008;99:341–349.
    1. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771–2777.
    1. Romero H, Schneider J. Different detection rates of HER-2/NEU overexpression in ovarian carcinoma using two different commercially available detection kits. Eur J Cancer. 1995;31A:1020–1021.
    1. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res. 2000;6:1854–1864.
    1. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007;97:391–397.
    1. Gazic B, Pizem J, Bracko M, Cufer T, Borstnar S, Pohar-Marinsek Z, Us-Krasovec M. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients. Cytopathology. 2008;19:294–302.
    1. Jensen V, Prasad AR, Smith A, Raju M, Wendel CS, Schmelz M, Leyva W, Warneke J, Krouse RS. Prognostic criteria for squamous cell cancer of the skin. J Surg Res. 2010;159:509–516.
    1. Vandenbroucke JP. Prospective or retrospective: what's in a name? BMJ. 1991;302:249–250.
    1. Kivela T, Grambsch PM. Evaluation of sampling strategies for modeling survival of uveal malignant melanoma. Invest Ophthalmol Vis Sci. 2003;44:3288–3293.
    1. Breslow NE, Chatterjee N. Design and analysis of two-phase studies with binary outcome applied to Wilms tumour prognosis. Appl Stat. 1999;48:457–468.
    1. Gray RJ. Weighted analyses for cohort sampling designs. Lifetime Data Anal. 2009;15:24–40.
    1. Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res. 2003;63:337–341.
    1. Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C, Nanus DM. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 2004;10:4096–4100.
    1. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
    1. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310.
    1. Wu Y, Takkenberg JJ, Grunkemeier GL. Measuring follow-up completeness. Ann Thorac Surg. 2008;85:1155–1157.
    1. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72:511–518.
    1. Ceriani RL, Chan CM, Baratta FS, Ozzello L, DeRosa CM, Habif DV. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer. 1992;51:343–354.
    1. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M. Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG) Br J Cancer. 1999;79:1752–1760.
    1. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25:2127–2132.
    1. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27:3757–3763.
    1. van Walraven C, Davis D, Forster AJ, Wells GA. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol. 2004;57:672–682.
    1. Beyersmann J, Wolkewitz M, Schumacher M. The impact of time-dependent bias in proportional hazards modelling. Stat Med. 2008;27:6439–6454.
    1. Rochon J. Issues in adjusting for covariates arising postrandomization in clinical trials. Drug Inf J. 1999;33:1219–1228.
    1. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145–157.
    1. Andersen P, Skovgaard LT. Regression with linear predictors. New York, NY: Springer; 2010.
    1. Cortese G, Andersen PK. Competing risks and time-dependent covariates. Biom J. 2010;52:138–158.
    1. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360:1381–1391.
    1. Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, Shao Y, Aherne W, Houlston R. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol. 2006;17:1810–1817.
    1. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27:5519–5528.
    1. Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med. 2000;19:441–452.
    1. McShane LM, Simon R. In: Prognostic factors in cancer. 2. Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind C, editor. New York, NY: Wiley-Liss; 2001. Statistical methods for the analysis of prognostic factor studies; pp. 37–48.
    1. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21:552–560.
    1. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist. 2006;11:624–629.
    1. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69:1071–1077.
    1. Schumacher M, Hollander N, Schwarzer G, Sauerbrei W. In: Handbook of Statistics in Clinical Oncology. 2. Crowley J, Ankerst DP, editor. Boca Raton, FL: Chapman; 2006. Prognostic factor studies; pp. 289–334.
    1. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503–1510.
    1. Feinstein AR. Multivariable Analysis: an Introduction. New Haven: Yale University Press; 1996.
    1. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710–718.
    1. Lubin JH, Gail MH. On power and sample size for studying features of the relative odds of disease. Am J Epidemiol. 1990;131:552–566.
    1. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–1057.
    1. Bentzen SM. Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys. 2001;49:513–518.
    1. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4–12.
    1. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. 2010.
    1. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201–210.
    1. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol. 2001;54:979–985.
    1. Pocock SJ, Collier TJ, Dandreo KJ, De Stavola BL, Goldman MB, Kalish LA, Kasten LE, McCormack VA. Issues in the reporting of epidemiological studies: a survey of recent practice. BMJ. 2004;329:883.
    1. Ottenbacher KJ, Ottenbacher HR, Tooth L, Ostir GV. A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. J Clin Epidemiol. 2004;57:1147–1152.
    1. Klebanoff MA, Cole SR. Use of multiple imputation in the epidemiologic literature. Am J Epidemiol. 2008;168:355–357.
    1. Kho ME, Eva KW, Cook DJ, Brouwers MC. The Completeness of Reporting (CORE) index identifies important deficiencies in observational study conference abstracts. J Clin Epidemiol. 2008;61:1241–1249.
    1. Falagas ME, Grigori T, Ioannidou E. A systematic review of trends in the methodological quality of randomized controlled trials in various research fields. J Clin Epidemiol. 2009;62:227–231.
    1. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387.
    1. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley and Sons Ltd; 2000.
    1. Harrell FE. , Jr. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York, NY: Springer; 2001.
    1. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer. 2003;89:605–611.
    1. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. Br J Cancer. 2003;89:431–436.
    1. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer. 2003;89:781–786.
    1. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89:232–238.
    1. Vittinghoff E, Glidden DV, McCulloch CE, Shiboski SC. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. New York, NY: Springer Science and Business Media Inc; 2005.
    1. Schumacher M, Holländer N, Schwarzer G, Sauerbrei W. In: Handbook of Statistics in Clinical Oncology. 2. Crowley J, Ankerst DP, editor. Boca Raton, FL: Chapman & Hall/CRC Press; 2006. Prognostic factor studies; pp. 289–333.
    1. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26:5512–5528.
    1. Hosmer DW, Lemeshow S, May S. Applied survival analysis: Regression modeling of time-to-event data. Hoboken, NJ: Wiley-Interscience; 2008.
    1. Royston P, Sauerbrei W. Multivariable model-building: A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester, UK: John Wiley; 2008.
    1. Dupont WD. Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data. Cambridge University Press, UK; 2009.
    1. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116:53–68.
    1. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991. Preparing to analyse data; pp. 122–151.
    1. Blettner M, Sauerbrei W. Influence of model-building strategies on the results of a case-control study. Stat Med. 1993;12:1325–1338.
    1. Mallows C. The zeroth problem. Am Stat. 1998;52:1–9.
    1. Chatfield C. Confessions of a pragmatic statistician. J R Stat Soc Ser D-STA. 2002;51:1–20.
    1. Bailar JC III. How to distort the scientific record without actually lying: truth, and the arts of science. Eur J Oncol. 2006;11:217–224.
    1. Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009;115:1021–1027.
    1. Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45:3291–3297.
    1. Wolkewitz M, Vonberg RP, Grundmann H, Beyersmann J, Gastmeier P, Barwolff S, Geffers C, Behnke M, Ruden H, Schumacher M. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crit Care. 2008;12:R44.
    1. Marubini E, Valsecchi M. Analysing Survival Data from Clinical Trials and Observational Studies. New York, NY: John Wiley and Sons Ltd; 1995.
    1. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag New York Inc.; 2001.
    1. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–2197.
    1. Simon R, Korn EL, McShane LM, Radmacher MD, Wright G, Zhao Y. Design and analysis of DNA microarray investigations. New York, NY: Springer; 2004.
    1. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York, NY: Springer-Verlag; 2009.
    1. Hastie T, Tibshirani R, Friedman JH. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York, NY: Springer-Verlag New York Inc.; 2009.
    1. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003;5:R242–R249.
    1. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–694.
    1. Kenward MG, Carpenter J. Multiple imputation: current perspectives. Stat Methods Med Res. 2007;16:199–218.
    1. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
    1. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982–1998.
    1. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J. EORTC Lung Cancer Group and Qualoty of Life Unit. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17:1698–1704.
    1. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Appl Stat. 1999;48:313–329.
    1. Pace NL. Independent predictors from stepwise logistic regression may be nothing more than publishable P values. Anesth Analg. 2008;107:1775–1778.
    1. Coradini D, Daidone MG, Boracchi P, Biganzoli E, Oriana S, Bresciani G, Pellizzaro C, Tomasic G, Di FG, Marubini E. Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol. 2000;18:2702–2709.
    1. Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol. 2003;179:8–15.
    1. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc. 1992;87:942–951.
    1. Abrahamowicz M, MacKenzie TA. Joint estimation of time-dependent and non-linear effects of continuous covariates on survival. Stat Med. 2007;26:392–408.
    1. Sauerbrei W, Royston P, Look M. A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. Biom J. 2007;49:453–473.
    1. Belsley DA, Kuh E, Welsch RE. Regression diagnostics: Identifying influential data and sources of collinearity. New York, NY: Wiley; 1980.
    1. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004;66:411–421.
    1. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Hofler H, Keller G. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer. 2009;45:3326–3335.
    1. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249–257.
    1. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453–473.
    1. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605.
    1. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446–1452.
    1. Davison AC, Hinkley DV. Bootstrap Methods and their Application. Cambridge University Press, UK; 1997.
    1. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141–1164.
    1. Chernick MR. Bootstrap Methods: A Guide for Practitioners and Researchers. New York, NY: Wiley; 2008.
    1. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–3444.
    1. Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008;14:428–434.
    1. Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat. 2009;116:131–143.
    1. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127–141.
    1. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678–686.
    1. Clark GM, Zborowski DM, Culbertson JL, Whitehead M, Savoie M, Seymour L, Shepherd FA. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2006;1:837–846.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.
    1. Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du BA, Kiechle-Schwarz M, Pfleiderer A. Cellular DNA content and survival in advanced ovarian carcinoma. Cancer. 1994;74:2509–2515.
    1. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer. 2006;107:90–98.
    1. Kommoss F, Pfisterer J, Idris T, Giese E, Sauerbrei W, Schafer W, Thome M, Pfleiderer A. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol. 1994;16:203–210.
    1. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
    1. Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method) BMJ. 1998;317:1572.
    1. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686–1689.
    1. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345–2352.
    1. Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res. 2004;10:822–824.
    1. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882–890.
    1. Watermann D, Madjar H, Sauerbrei W, Hirt V, Prompeler H, Stickeler E. Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep. 2004;11:905–910.
    1. Vormittag L, Gleiss A, Scheithauer W, Lang F, Laengle F, Kornek GV. Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. Oncology. 2009;77:140–146.
    1. Efron B, Tibshirani RJ. Introduction to the bootstrap. Chapman & Hall/CRC Press; 1994.
    1. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res. 2009;15:4680–4685.
    1. Haffty BG, Yang Q, Moran MS, Tan AR, Reiss M. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys. 2008;71:1006–1013.
    1. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15:4674–4679.
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694.
    1. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:452–474.
    1. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40:e380–e389.
    1. Mupparapu M, Kim IH. Calcified carotid artery atheroma and stroke: a systematic review. J Am Dent Assoc. 2007;138:483–492.
    1. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M, Abrams KR, Moreno S, McAllister KS, Palmer S, Kaski JC, Timmis AD, Hingorani AD. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med. 2010;7:e1000286.
    1. Huber GF, Zullig L, Soltermann A, Roessle M, Graf N, Haerle SK, Studer G, Jochum W, Moch H, Stoeckli SJ. Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer. 2011;11:217–218.
    1. Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I. Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med. 2010;8:19.
    1. Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients. Breast Cancer Res. 2009;11:R67.
    1. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol. 2007;25:5194–5202.
    1. Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Vigano MG, Villa E, Corti A. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer. 2007;110:845–853.
    1. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004;22:1242–1252.
    1. Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R, Jezequel P. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer. 2009;101:166–173.
    1. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer. 2009;115:1234–1244.
    1. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102:152–160.
    1. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069.
    1. Lagakos SW. The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006;354:1667–1669.
    1. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
    1. Greenland S. Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med. 1983;2:243–251.
    1. Willett WC. The search for truth must go beyond statistics. Epidemiology. 2008;19:655–656.
    1. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2004;23:2509–2525.
    1. Royston P, Sauerbrei W, Ritchie A. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer. 2004;90:794–799.
    1. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000;19:2595–2609.
    1. Royston P, Sauerbrei W. Interactions between treatment and continuous covariates: a step toward individualizing therapy. J Clin Oncol. 2008;26:1397–1399.
    1. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;59:1087–1091.
    1. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol. 2006;59:1102–1109.
    1. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol. 2008;26:3721–3726.
    1. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–835.
    1. Holländer N, Sauerbrei W, Schumacher M. Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med. 2004;23:1701–1713.
    1. van Walraven C, Hart RG. Leave 'em alone - why continuous variables should be analyzed as such. Neuroepidemiology. 2008;30:138–139.
    1. Vickers AJ, Lilja H. Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem. 2009;55:15–17.
    1. Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res. 2008;14:5977–5983.
    1. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Applied Statistics. 1994;43:467.
    1. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008;19:640–648.
    1. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PJ, Von EE, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE. 2008;3:e3081.
    1. Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in meta-analysis. Stat Methods Med Res. 2005;14:515–524.
    1. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer. 2007;43:2559–2579.
    1. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55–64.
    1. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst. 2005;97:1023–1025.
    1. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L. Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol. 2011;8:171–176.
    1. Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof. 2008;31:370–389.
    1. Sauerbrei W, Holländer N, Riley RD, Altman DG. Evidence-based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Commun Stat Theory Methods. 2006;35:1333–1342.
    1. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem. 2008;54:1101–1103.
    1. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003;362:1439–1444.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera